We serve Chemical Name:6-chloro-3-methoxy-2-methylpyridine CAS:129692-13-3 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:6-chloro-3-methoxy-2-methylpyridine
CAS.NO:129692-13-3
Synonyms:6-chloro-3-methoxy-2-methylpyridine
Molecular Formula:C7H8ClNO
Molecular Weight:157.59800
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:219.237ºC at 760 mmHg
Density:1.168g/cm3
Index of Refraction:1.516
PSA:22.12000
Exact Mass:157.02900
LogP:2.05200
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 6-chloro-3-methoxy-2-methylpyridine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,6-chloro-3-methoxy-2-methylpyridine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,6-chloro-3-methoxy-2-methylpyridine Use and application,6-chloro-3-methoxy-2-methylpyridine technical grade,usp/ep/jp grade.
Related News: The two trials studied similar patient populations, Tendler said, but VMP was an old standard of care that’s not really used today in the U.S. Still, Tendler believes the two regimens may both have roles to play based on each patient’s ability to tolerate them. Whichever cocktail physicians choose, the two phase 3 studies have confirmed the benefit of Darzalex in transplant-ineligible patients, he added. 6-chloro-3-methoxy-2-methylpyridine manufacturer J&J, in a statement, confirmed that the FDA authorized the two batches, but did not acknowledge the doses regulators decided should be tossed. 6-chloro-3-methoxy-2-methylpyridine supplier Featured APIs: Production capacity continues to expand, targeted patents expire. Original research drugs: industry entry barriers are high, performance stability and certainty are high. 6-chloro-3-methoxy-2-methylpyridine vendor The two trials studied similar patient populations, Tendler said, but VMP was an old standard of care that’s not really used today in the U.S. Still, Tendler believes the two regimens may both have roles to play based on each patient’s ability to tolerate them. Whichever cocktail physicians choose, the two phase 3 studies have confirmed the benefit of Darzalex in transplant-ineligible patients, he added. 6-chloro-3-methoxy-2-methylpyridine factory J&J, in a statement, confirmed that the FDA authorized the two batches, but did not acknowledge the doses regulators decided should be tossed.
